Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
In an attempt to make Systematic Investments Plans (SIPs) more affordable for the investors, the SBI Mutual Fund in ...
An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...
New packaging solution ensures all take-home products are recyclable through most curb-side programsBELVIDERE, NJ, Feb. 13, ...
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...
Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...
SBI Mutual Fund, in collaboration with State Bank of India (SBI) and Paytm, has introduced the JanNivesh SIP scheme, allowing ...